{"type":"trials","record":{"id":42059,"source_id":"clinicaltrials-gov","external_id":"NCT05662943","title":"Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV","brief_summary":"The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Kim's Eye Hospital","enrollment":135,"countries":["South Korea"],"start_date":"2022-12-05","completion_date":"2023-11-30","last_update_date":"2023-12-14","source_url":"https://clinicaltrials.gov/study/NCT05662943","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Kim's Eye Hospital","interventions":["Intravitreal aflibercept injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Changes in visual acuity — Through study completion, an average of 20 months","Proportion of patients who exhibited deterioration of ≥0.3 logMAR BCVA — Through study completion, an average of 20 mon…","Difference in the BCVA change, according to MNV subtype — Through study completion, an average of 20 months","Degree of visual deterioration according to the treatment period — Through study completion, an average of 20 months","Degree of visual deterioration according to the height of SRF — Through study completion, an average of 20 months","Degree of visual deterioration according to the fluctuation of SRF height — Through study completion, an average of 20…","Comparison of visual outcomes between the following three groups (mean SRF height <100 µm vs ≥100 µm, <200 µm vs ≥200 µ…","Risk factor of developing deterioration of ≥0.2 logMAR BCVA — Through study completion, an average of 20 months","Proportion of patients in whom the intraretinal fluid (IRF) developed during treatment tolerating SRF — Through study c…","Difference in visual outcome between patients with and without IRF development — Through study completion, an average o…","Risk factors of IRF development — Through study completion, an average of 20 months","The incidence of vision-threatening event such as large submacular hemorrhage or tear of retinal pigment epithelium — T…","The incidence of SRF resolution without shortening injection interval — Through study completion, an average of 20 mont…"],"design_description":null,"source_has_results":false},"controlled_terms":["Polypoidal Choroidal Vasculopathy","Choroidal Neovascularization","Age-Related Macular Degeneration","Intravitreal aflibercept injection"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05662943","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-12-05 to 2023-11-30","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.914Z","intervention":["Intravitreal aflibercept injection"],"participants":135,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Changes in visual acuity — Through study completion, an average of 20 months","Proportion of patients who exhibited deterioration of ≥0.3 logMAR BCVA — Through study completion, an average of 20 mon…","Difference in the BCVA change, according to MNV subtype — Through study completion, an average of 20 months","Degree of visual deterioration according to the treatment period — Through study completion, an average of 20 months","Degree of visual deterioration according to the height of SRF — Through study completion, an average of 20 months","Degree of visual deterioration according to the fluctuation of SRF height — Through study completion, an average of 20…","Comparison of visual outcomes between the following three groups (mean SRF height <100 µm vs ≥100 µm, <200 µm vs ≥200 µ…","Risk factor of developing deterioration of ≥0.2 logMAR BCVA — Through study completion, an average of 20 months","Proportion of patients in whom the intraretinal fluid (IRF) developed during treatment tolerating SRF — Through study c…","Difference in visual outcome between patients with and without IRF development — Through study completion, an average o…","Risk factors of IRF development — Through study completion, an average of 20 months","The incidence of vision-threatening event such as large submacular hemorrhage or tear of retinal pigment epithelium — T…","The incidence of SRF resolution without shortening injection interval — Through study completion, an average of 20 mont…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42059","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}